| 1 |
34534577 | Combined Cyclin-Dependent Kinase Inhibition Overcomes MAPK/Extracellular Signal-Regulated Kinase Kinase Inhibitor Resistance in Plexiform Neurofibroma of Neurofibromatosis Type I. | 2022 Mar |
1 |
| 2 |
35417031 | Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway. | 2022 May |
1 |
| 3 |
32816920 | CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer. | 2021 May |
2 |
| 4 |
32375399 | Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib. | 2020 May 4 |
1 |
| 5 |
33125153 | Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer. | 2020 Dec |
1 |
| 6 |
31207099 | Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1-involved pathway. | 2019 Aug |
4 |
| 7 |
29233910 | Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. | 2018 Mar |
1 |
| 8 |
28207834 | A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer. | 2017 |
1 |
| 9 |
27486754 | Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer. | 2016 Aug 30 |
1 |
| 10 |
27550941 | Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2. | 2016 Nov |
1 |
| 11 |
25395429 | Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. | 2015 Jan 15 |
2 |
| 12 |
25947565 | A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. | 2015 Aug |
1 |
| 13 |
25962959 | Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer. | 2015 Jun 20 |
2 |
| 14 |
24362465 | Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. | 2014 Mar |
1 |
| 15 |
25107301 | Dinaciclib for the treatment of breast cancer. | 2014 Sep |
3 |
| 16 |
25217392 | Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. | 2014 Nov |
1 |
| 17 |
25289887 | MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis. | 2014 |
1 |
| 18 |
23053255 | Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. | 2012 Dec |
1 |